Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126922 | PMC |
| http://dx.doi.org/10.1016/j.gaceta.2015.02.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New reverse sum Revan indices for physicochemical and pharmacokinetic properties of anti-filovirus drugs.
Front Chem
December 2024
Department of Mathematics, School of Advanced Sciences, Vellore Institute of Technology, Chennai, Tamil Nadu, India.
Ebola and Marburg viruses, biosafety level 4 pathogens, cause severe hemorrhaging and organ failure with high mortality. Although some FDA-approved vaccines or therapeutics like Ervebo for Zaire Ebola virus exist, still there is a lack of effective therapeutics that cover all filoviruses, including both Ebola and Marburg viruses. Therefore, some anti-filovirus drugs such as Pinocembrin, Favipiravir, Remdesivir and others are used to manage infections.
View Article and Find Full Text PDFNucleocapsid assembly drives Ebola viral factory maturation and dispersion.
Cell
December 2024
Schaller Research Groups, Department of Infectious Diseases, Virology, Heidelberg University, Heidelberg, Germany; BioQuant, Heidelberg University, Heidelberg, Germany. Electronic address:
Article Synopsis
- Viral factories (VFs) are membrane-less organelles where negative-sense RNA viruses, like Ebola, replicate and encapsidate their genomes.
- Using advanced imaging techniques, researchers observed how viral nucleocapsids (NCs) change from loose formations to compact structures during the infection process.
- The study found that as VFs mature, they become less spherical and more integrated with cellular components, which likely aids in the transportation of NCs for virus budding.
Multiple cell types support productive infection and dynamic translocation of infectious Ebola virus to the surface of human skin.
Sci Adv
January 2025
Graduate Program in Immunology, University of Iowa, Iowa City, IA 52242, USA.
Ebola virus (EBOV) causes severe human disease. During late infection, EBOV virions are on the skin's surface; however, the permissive skin cell types and the route of virus translocation to the epidermal surface are unknown. We describe a human skin explant model and demonstrate that EBOV infection of human skin via basal media increases in a time-dependent and dose-dependent manner.
View Article and Find Full Text PDFClinical advancements in mRNA vaccines against viral infections.
Clin Immunol
December 2024
Department of Microbiology, Gachon University College of Medicine, Incheon, Republic of Korea; Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Republic of Korea; Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon, Republic of Korea; Korea mRNA Vaccine Initiative, Gachon University, Seongnam, Republic of Korea. Electronic address:
Over the last decade, mRNA vaccines development has shown significant advancement, particularly during the COVID-19 pandemic. This comprehensive review examines the efficacy of pivotal vaccines against emerging COVID-19 variants and strategies for enhancing vaccine effectiveness. It also explores the versatility of mRNA technology in addressing other infectious diseases such as influenza, respiratory syncytial virus, HIV, cytomegalovirus, Ebola, Zika, Rabies, and Nipah viruses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!